global bleeding disorders drugs market size, share and forecast 2026 | techsci research
DESCRIPTION
According to #TechSci Research report, the Global Bleeding Disorders Drugs Market is expected to grow at robust rate with a CAGR of 8.44% in value terms to reach USD24078.16 million by 2026. Report URL - https://bit.ly/331x8OL Visit our website @ https://www.techsciresearch.com/ For more market research news visit our blog: https://techsciblog.com/TRANSCRIPT
MARKET INTELLIGENCE . CONSULTINGwww.techsciresearch.com
GLOBAL BLEEDING DISORDERS DRUGS MARKET
FORECAST & OPPORTUNITIES
2016 – 2026
2
Scope of ReportProduct of Interest (POI): Bleeding Disorders Drugs
Review Period
2016 – 2019
Base Year
2020
Estimated Year
2021
Forecast Period
2022 – 2026
Year Range
Bleeding disorders are a group of conditions tMarket SegmentationDRUG TYPE
• Plasma-derived Coagulation
Factor Concentrates
• Recombinant Coagulation
Factor Concentrates
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Others
GENDER
• Male
• Female
DISTRIBUTION CHANNEL
• Hospital Pharmacies
• Retail Pharmacies
• Online
GLOBAL BRINE MANAGEMENT TECHNOLOGY
DISEASE TYPE
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others
END USER
• Hospitals
• Hemophilia Treatment Centers
• Research Institutes
• Others
3
Table of Contents
S. No. Contents Page No.
1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Bleeding Disorders Drugs Market
4. Executive Summary
5. Voice of Customer
5.1. Brand Awareness
5.2. Patients Satisfaction
5.3. Factors driving the global bleeding disorder market
6. Global Bleeding Disorders Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1.By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor
Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
6.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
6.2.4. By Gender (Male v/s Female)
6.2.6. By End User (Hospitals, Hemophilia Treatment Centers, Research Institutes, Others)
6.2.6. By Company (2020)
6.2.7. By Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)
6.3. Product Market Map
4
Table of Contents
S. No. Contents Page No.
7. Asia Pacific Bleeding Disorders Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Disease Type
7.2.3. By Distribution Channel
7.2.4. By Gender
7.2.5. By End User
7.2.6. By Country (India; China; Japan; Australia; South Korea)
7.3. Asia-Pacific: Country Analysis
7.3.1. India Bleeding Disorders Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Disease Type
7.3.1.2.3. By Distribution Channel
7.3.1.2.4. By Gender
7.3.1.2.5. By End User
5
Table of Contents
S. No. Contents Page No.
7.3.2. China Bleeding Disorders Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Disease Type
7.3.2.2.3. By Distribution Channel
7.3.2.2.4. By Gender
7.3.2.2.5. By End User
7.3.3. Japan Bleeding Disorders Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Disease Type
7.3.3.2.3. By Distribution Channel
7.3.3.2.4. By Gender
7.3.3.2.5. By End User
7.3.4. Australia Bleeding Disorders Drugs Market Outlook
6
Table of Contents
S. No. Contents Page No.
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Disease Type
7.3.4.2.3. By Distribution Channel
7.3.4.2.4. By Gender
7.3.4.2.5. By End User
7.3.5. South Korea Bleeding Disorders Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Disease Type
7.3.5.2.3. By Distribution Channel
7.3.5.2.4. By Gender
7.3.5.2.5. By End User
8. Europe Bleeding Disorders Drugs Market Outlook
7
Table of Contents
S. No. Contents Page No.
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Disease Type
8.2.3. By Distribution Channel
8.2.4. By Gender
8.2.5. By End User
8.2.6. By Country (Germany; United Kingdom; France; Italy; Spain)
8.3. Europe: Country Analysis
8.3.1. France Bleeding Disorders Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Disease Type
8.3.1.2.3. By Distribution Channel
8
Table of Contents
S. No. Contents Page No.
8.3.1.2.4. By Gender
8.3.1.2.5. By End User
8.3.2. Germany Bleeding Disorders Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Disease Type
8.3.2.2.3. By Distribution Channel
8.3.2.2.4. By Gender
8.3.2.2.5. By End User
8.3.3. United Kingdom Bleeding Disorders Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Disease Type
8.3.3.2.3. By Gender
8.3.3.2.4. By Organization Size
9
Table of Contents
S. No. Contents Page No.
8.3.3.2.5. By End User
8.3.4. Italy Bleeding Disorders Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Disease Type
8.3.4.2.3. By Distribution Channel
8.3.4.2.4. By Gender
8.3.4.2.5. By End User
8.3.5. Spain Bleeding Disorders Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Disease Type
8.3.5.2.3. By Distribution Channel
8.3.5.2.4. By Gender
10
Table of Contents
S. No. Contents Page No.
8.3.5.2.5. By End User
9. North America Bleeding Disorders Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Disease Type
9.2.3. By Distribution Channel
9.2.4. By Gender
9.2.5. By End User
9.2.6. By Country (United States; Canada; Mexico)
9.3. North America: Country Analysis
9.3.1. United States Bleeding Disorders Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Disease Type
9.3.1.2.3. By Distribution Channel
9.3.1.2.4. By Gender
9.3.1.2.5. By End User
9.3.2. Mexico Bleeding Disorders Drugs Market Outlook
11
Table of Contents
S. No. Contents Page No.
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Disease Type
9.3.2.2.3. By Distribution Channel
9.3.2.2.4. By Gender
9.3.2.2.5. By End User
9.3.3. Canada Bleeding Disorders Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Disease Type
9.3.3.2.3. By Distribution Channel
9.3.3.2.4. By Gender
9.3.3.2.5. By End User
10. South America Bleeding Disorders Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
12
Table of Contents
S. No. Contents Page No.
10.2.2. By Disease Type
10.2.3. By Distribution Channel
10.2.4. By Gender
10.2.5. By End User
10.2.6. By Country (Brazil; Argentina; Colombia)
10.3. South America: Country Analysis
10.3.1. Brazil Bleeding Disorders Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1 By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Disease Type
10.3.1.2.3. By Distribution Channel
10.3.1.2.4. By Gender
10.3.1.2.5. By End User
10.3.2. Argentina Bleeding Disorders Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1 By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Disease Type
10.3.2.2.3. By Distribution Channel
13
Table of Contents
S. No. Contents Page No.
10.3.2.2.4. By Gender
10.3.2.2.5. By End User
10.3.3. Colombia Bleeding Disorders Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1 By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.2.2.2. By Disease Type
10.3.2.2.3. By Distribution Channel
10.3.2.2.4. By Gender
10.3.2.2.5. By End User
11. Middle East & Africa Bleeding Disorders Drugs Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Type
11.2.2. By Disease Type
11.2.3. By Distribution Channel
11.2.4. By Gender
11.2.5. By End User
11.2.6. By Country (UAE; Saudi Arabia; South Africa)
11.3. Middle East & Africa : Country Analysis
14
Table of Contents
S. No. Contents Page No.
11.3.1. South Africa Bleeding Disorders Drugs Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Type
11.3.1.2.2. By Disease Type
11.3.1.2.3. By Distribution Channel
11.3.1.2.4. By Gender
11.3.1.2.5. By Industry
11.3.2. Saudi Arabia Bleeding Disorders Drugs Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Type
11.3.2.2.2. By Disease Type
11.3.2.2.3. By Distribution Channel
11.3.2.2.4. By Gender
11.3.2.2.5. By End User
11.3.3. UAE Bleeding Disorders Drugs Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
15
Table of Contents
S. No. Contents Page No.
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Type
11.3.3.2.2. By Disease Type
11.3.3.2.3. By Distribution Channel
11.3.3.2.4. By Gender
11.3.3.2.5. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Competition Outlook
14.2. Global Players Profiled (Leading Companies)
14.2.1. Bayer AG
14.2.2. Pfizer Inc
14.2.3. Grifols S.A.
14.2.4. Octapharma AG
14.2.5. Ferring Pharmaceuticals SA
14.2.6. Sanofi SA
14.2.7 Baxter International Inc.
16
Table of Contents
S. No. Contents Page No.
14.2.8. F. Hoffmann-La Roche Ltd.
14.2.9. Takeda Pharmaceuticals Ltd.
14.2.10. Novo Nordisk A/S
14.2.11. Novartis AG
14.2.12. CSL Limited
14.2.13. Teva Pharmaceutical Industries Ltd.
14.2.14. Cadila Healthcare Ltd
14.2.15. Johnson & Johnson International Inc
14. Strategic Recommendations
15. About Us & Disclaimer
RESEARCH METHODOLOGY
18
Research Methodology
✓ Identifying Key Opinion
Leaders
✓ Questionnaire Design
✓ In-depth Interviews
Data Collection
Developing List of Respondents
Formulating Questionnaire
Market Profiling
Data Validation
Data Analysis
In-depth secondary research was conducted to
determine top players in the global bleeding
disorders drugs market, overall market size and segmental market size.
In order to conduct industry experts’
interviews, TechSci formulated a detailed
discussion guide.
List of industry players and industry
specialists was developed.
TechSci conducted interviews with
industry experts and industry players for data collection and
verification.
Data obtained as a result of primary and secondary research was
validated through rigorous
triangulation.
The data was scrutinized using MS-Excel, statistical
tools and internal proprietary database to obtain qualitative and
quantitative insights about the global bleeding
disorders drugs market.
Data Collection
Data Filter& Analysis
Research &Intelligence
ActionableInsights
BusinessSolution
Primary Research Desk Research Company Analysis
✓ Recent Developments
✓ Market Changing
Aspects/Dynamics
✓ Government Policies
✓ Conclusion
✓ Market Participants
✓ Key Strengths
✓ LinkedIn✓ TechSci Internal
Database
✓ Factiva✓ Hoovers
Paid Sources
✓ Company Websites✓ Company Annual
Reports✓ White Paper Study✓ Financial Reports✓ Investor
Presentations✓ Regulatory Body✓ Associations, etc.
Secondary Research
Primary Research
19
Research Methodology
Baseline Methodology
Our dedicated team of industry experts has monitored and analyzed various aspects of the global bleeding disorders drugs market. The team
has analyzed the outlook of various segments of this market, while considering the major influencing factors such as increasing concerns for
blood disorders among the worldwide population. The study includes market forecasting, which would enable our clients to take better
decisions while planning their strategy to achieve sustainability in the global bleeding disorders drugs market.
Methodology Followed for Calculation of Market Size:
• Market Size by Value: Market size, in terms of value, for the year 2020 was calculated based on information collected through exhaustive
secondary research and primary surveys, with various key opinion leaders/stakeholders, such as companies, suppliers, distributors, market
influencers & end users, industry experts, and other industry participants.
• The team interviewed more than 15 – 20 companies, 100 – 120 end users, 15 – 20 industry experts and other value chain stakeholders in the
global bleeding disorders drugs market to obtain the overall market size from 2016 to 2020, which was validated by the Delphi technique.
Taking standard deviation into consideration, the market size was averaged out, to arrive at the market size data during 2016-2020.
20
Research Methodology
• Respondents were asked about the current and future market growth rates, market shares by drug type, by disease type, by distribution
channel, and by gender, and by end user and by region. Removing the outlier responses, the geometric mean of growth estimates and
provider wise revenue shares generated across various segments were considered, to arrive at the final revenue shares. Revenue shares
generated across various segments were further triangulated from other stakeholders.
Methodology Followed for Calculation of Market Shares:
• Market shares by drug type, by disease type, by distribution channel, and by gender, and by end user and by region. were calculated based
on the responses received through primary surveys with industry experts, in which the respondents were asked about the market shares or
revenue generated from various segments of the market. The final shares were calculated by taking the geometric mean of the responses
gathered from key opinion leaders after eliminating the outliers.
Methodology Followed for Forecasting:
• TechSci Research performed periodical checks on data collected through the surveys with logic checks and analyzed the survey results in
SPSS/Tableau Software.
• Data triangulation techniques were applied to fill the gaps and to present a more meaningful picture of the market. To forecast global
bleeding disorders drugs market, TechSci Research used various forecast techniques such as:
✓ Moving Average
✓ Time Series Analysis
✓ Regression Analysis
✓ Econometric and Judgmental Analysis
21
Research Methodology
TechSci Research used its own forecast tool, which is based on the growth of various allied industries in respective regions. TechSci
Research also used the impact analysis during short, medium and long term period to estimate the demand and to reach accurate
market numbers. It should be noted that the figures compiled are only for the organized market including market share data. The
currency used in the report is the United States Dollar (USD), with the market size indicated in USD million.
Partial List of Companies Interviewed Key Secondary Sources
▪ Bayer AG
▪ Pfizer Inc.
▪ Grifols S.A.
▪ Octapharma AG
▪ Ferring Pharmaceuticals SA
▪ Sanofi SA
▪ Baxter International Inc.
▪ F. Hoffmann-La Roche Ltd.
▪ Takeda Pharmaceuticals Ltd.
▪ Novo Nordisk A/S
▪ Novartis AG
▪ CSL Limited
▪ Teva Pharmaceutical Industries Ltd.
▪ Cadila Healthcare Ltd
▪ Johnson & Johnson International Inc
▪ World Bank
▪ TechSci Research Proprietary Database & Knowledge
Repository
▪ Company Annual Reports
▪ Industry Magazines
▪ Industry Reports
▪ News Dailies
▪ Credible Paid Databases
22
Industry Brief
According to TechSci Research report, “Global Bleeding Disorders Treatment Market By Drug Type (Plasma-derived Coagulation
Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others) By
Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online) By End User (Clinics, Hospitals, Research Institutes, Others) By Region, Competition Forecast & Opportunities,
2026”, the Global Bleeding disorders treatment is expected to grow at a promising rate during the forecast period.
Due to the onset of COVID-19 and imposition of complete lockdown to mitigate the coronavirus, there has been shutdown of many
manufacturing units and disruption in the supply chain resulting in interrupted production and lesser supply of the implants all around
the globe. Also, the economy has been adversely affected in many countries resulting in the hinderance to the growth of the Bleeding
disorders treatment market. Hospitals and clinics were intensely involved in the treatment and recovery plans from the pandemic and
thus the market for all other health resources slowed down. However, after relief from lockdown market is again going to pick up pace
to grow significantly.
Global bleeding disorders treatment market is segmented by drug type, disease type, distribution channel, end user, and regional
distribution. Based on regional distribution the market considers five regions of the world, Asia-Pacific, North America, South America,
MEA, and Europe. North America and Europe are projected to dominate the market owing to the facts that the treatment is more
affordable, and healthcare is more feasible for the patients. Also, Government and private institutes are actively creating awareness
regarding the blood disorders and their treatments that is supporting the dominance of the region around the world. Asia-Pacific
region is expected to gain more market shares in the forecast period because of the growing economies like India and China in the
region.
Some of the major competitors in the market are Bayer AG, Pfizer Inc., Grifols S.A., Octapharma AG, Sun Pharmaceuticals
Industries Ltd., Ferring Pharmaceuticals SA, Amgen Inc., Sanofi SA, Baxter International Inc., F. Hoffmann-La Roche Ltd., Takeda
Pharmaceuticals Ltd., Novo Nordisk A/S, Novartis AG, Eli Lilly and Company Ltd., Gilead Sciences Inc., among others. The
companies are focusing on extensive research and developments activities to stay competitive in the market. Other competitive
strategies include formation of alliances and partnerships.
“The Global Bleeding Disorder Treatment Market is anticipatory toward an exponential growth in upcoming five years, but market for
sure sees some challenges. New investors or competitors can focus over issues like expensive hemophilia drugs and weak
reimbursements by the health insurance companies. If these challenges are overcome the market can be easily dominated,” said Mr.
Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.
23
Sample Data - Snapshot
Global Bleeding Disorders Drugs Market Size, By Value (USD Million), 2016–2026F
5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00
2016 2020 2021E 2026F
By Value (USD Million)
CAGR By Value
YY%CAGR By Value
XX%North America Bleeding Disorders Drugs Market Share, By Drug Type , By Value, 2016–2026F
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
25%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
20%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
10%
2016
2017
2018
2019
2020
2021E
2022F
2023F
2024F
2025F
2026F
Plasma-derived Coagulation Factor Concentrates Recombinant Coagulation Factor ConcentratesDesmopressin AntifibrinolyticsFibrin Sealants Others
Canada Bleeding Disorders Drugs Market Share, By Disease Type, By Value, 2016–2026F
25%25%25%25%25%25%25%25%25%25%25%
25%25%25%25%25%25%25%25%25%25%25%
30%30%30%30%30%30%30%30%30%30%30%
20%20%20%20%20%20%20%20%20%20%20%
2016
2018
2020
2022F
2024F
2026F
Hemophilia A Hemophilia B Von Willebrand Disease Others
24
Report Ordering
Report Name: GLOBAL BLEEDING DISORDERS DRUGS MARKET
FORECAST & OPPORTUNITIES
2016 – 2026
To View Sample OR Purchase Report
License Type Price
Single User License $4450
Multi-User License $5450
Custom Research License $9450
About Us & Disclaimer
TechSci Research is a global market research and consulting company with offices in the US, UK and India. TechSci Research provides market research reports in
number of areas to organizations. The company uses innovative business models that focus on improving productivity, while ensuring creation of high-quality reports. The
proprietary forecasting models use various analyses of both industry-specific and macroeconomic variables on a state-by-state basis to produce a unique ‘bottom-up’
model of a country, regional and global industry prospects. Combined with the detailed analysis of company activity and industry trends, the result is a uniquely rich
evaluation of the opportunities available in the market.
Related Reports
• Global CAR-T Cell Therapy Market By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Multiple
Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Others), By Targeted Antigen(CD 19, CD22, BCMA (B-Cell
Maturation Antigen), HER1, HER2, Meso, EGFRvlll, Others), By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel),
JCAR017 (Lisocabtagene Maraleucel), bb2121), By End User (Hospitals, Cancer Treatment Centers, Others), By Region, Forecast &
Opportunities, 2025
• Global Oncology Drugs Market By Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs), By Therapy (Chemotherapy, Targeted
Therapy, Immunotherapy, Hormonal Therapy, Others), By Drug Therapy (Adjuvant, Neoadjuvant and Concurrent), By Route of Administration
(Oral, Intravenous, Subcutaneous, Others), By Gender (Male, Female), By Cancer Type (Lung Cancer, Stomach Cancer, Others), By Distribution
Channel (Hospital Pharmacies, Others), By Region, Competition, Forecast & Opportunities, 2025
The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely,accurate or complete. TechSci Research has taken due care and caution in compilation of data as this has been obtained from various sources including which it considersreliable and firsthand. However, TechSci Research does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors oromissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of thisreport. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative marketsize and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior approval of TechSci Research.
TechSci Research – North America708 Third Avenue, Manhattan,
New York, United StatesTel: +1- 646- 360- 1656
Email: [email protected] www.techsciresearch.com
Disclaimer
TechSci Research – Europe54, Old brook, Bretton,
Peterborough, United Kingdom
Email: [email protected] www.techsciresearch.com
TechSci Research – Asia-PacificB – 44, Sector – 57, Noida, National Capital
Region, U.P. - IndiaTel: +91-120-4523900
Email: [email protected] www.techsciresearch.com